概览
临床研究
联系信息
概览
仁爱临床研究中心旨在进行有素质和符合道德的临床试验，以促进医学治疗的发展。我们在不同学科进行各种临床试验，包括癌症、高血压和糖尿病。
我们的临床试验都由良好实践(GCP)认证的医生进行。配合药剂师、实验室的科学家和护士，患者在临床试验的过程中得到仔细的跟进。
良好的临床实践指
“一个用于临床试验的设计，进行，执行，监视，审核，记录，分析和报告的标准，可确保数据和报告的结果可信且准确，并确保试验对象的权利，受到完整性和机密性的保护。”
SHOULD I VOLUNTEER?
HARUSKAH SAYA MENJADI SUKARELAWAN?
我应该成为志愿受试者吗?
临床研究
我们正在进行临床试验的项目如下:
| No. | Protocol ID | 研究题目 | 研究员 |
|---|---|---|---|
| 1. | Samson-II | A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer Download to learn more |
Dr Sanjeev Chopra / Dr Hayani Abd. Wahid |
欲知更多详情，请联系各试验项目的研究院或卢秀玫女士： +606-285 2946 / loo.sm@mahkotamedical.com
仍在进行但已停止招募的试验：
| No. | Protocol ID | 研究题目 | 研究员 |
|---|---|---|---|
| 1. | Z100-01 | Randomized, Double-Blind, Placebo-Controlled Trial of Z-100 Plus Radiation Therapy in Patients With Local Advanced Cervical Cancer – A Phase III Trial | Dr Sanjeev Chandra Joshi |
| 2. | ARISE | A multi-center prospective non-interventional study investigating the clinical effectiveness of Ryzodeg® (Insulin Degludec/Insulin Aspart) in patients with type 2 diabetes mellitus in a real world setting | Dr Lim Siang Chin / Dr Yew Shiong Shiong |
已经完成并结束的试验项目：
| No. | Protocol ID | 研究题目 | 研究员 |
|---|---|---|---|
| 1. | IHN01 | Phase III double-blind, placebo-controlled study of post-operative adjuvant concurrent chemoradiotherapy (CTRT) with or without Nimotuzumab for Stage III/IV head and neck squamous cell cancer | Dr Sanjeev Chandra Joshi |
| 2. | EXCELLENCE | An Observational Study on Prevalent AntiHypertensive Prescription Practices in Private Hospitals in Malaysia | Dr Ashok Philip / Dr Yew Shiong Shiong |
| 3. | GP13-301 | A randomized, controlled, double-blind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera® plus cyclophosphamide, vincristine, prednisone, followed by GP2013 or MabThera® maintenance therapy in patients with previously untreated, advanced stage follicular lymphoma | Dr Kok Keng Weng |
| 4. | BV-NSCLC-002 | A Phase III, open-label, multicentre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, late stage (IIIb/IV) biomarker positive Non Small Cell Lung Carcinoma (NSCLC) patients eligible to receive standard treatment and supportive care | Dr Sanjeev Chandra Joshi |
| 5. | B7391003 | A Phase 3 Randomized, Double-Blind Study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Pacitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer | Dr Sanjeev Chandra Joshi |
| 6. | IMCL CP12-0919 | A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH) | Dr Jayendran Dharmaratnam |
| 7. | LA-EP06-302 | Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta® | Dr Jayendran Dharmaratnam |
